JP5661994B2 - Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect - Google Patents
Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect Download PDFInfo
- Publication number
- JP5661994B2 JP5661994B2 JP2008223166A JP2008223166A JP5661994B2 JP 5661994 B2 JP5661994 B2 JP 5661994B2 JP 2008223166 A JP2008223166 A JP 2008223166A JP 2008223166 A JP2008223166 A JP 2008223166A JP 5661994 B2 JP5661994 B2 JP 5661994B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition
- fatigue
- weight
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 24
- 230000036548 skin texture Effects 0.000 title claims description 18
- 230000037303 wrinkles Effects 0.000 title description 24
- 230000000694 effects Effects 0.000 title description 19
- 238000002360 preparation method Methods 0.000 title description 16
- 230000006872 improvement Effects 0.000 title description 11
- 230000002180 anti-stress Effects 0.000 title description 8
- 230000002265 prevention Effects 0.000 title description 7
- 230000002929 anti-fatigue Effects 0.000 title description 5
- 239000009538 yokuinin Substances 0.000 claims description 29
- 241000736199 Paeonia Species 0.000 claims description 20
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 19
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 11
- 235000017803 cinnamon Nutrition 0.000 claims description 11
- 230000027758 ovulation cycle Effects 0.000 claims description 9
- 230000003821 menstrual periods Effects 0.000 claims description 4
- 244000077995 Coix lacryma jobi Species 0.000 claims description 2
- 241000209205 Coix Species 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 61
- 206010016256 fatigue Diseases 0.000 description 29
- 239000000284 extract Substances 0.000 description 26
- 239000003826 tablet Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 230000035882 stress Effects 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 241000411851 herbal medicine Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001550 testis Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 244000144730 Amygdalus persica Species 0.000 description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000029849 luteinization Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002889 sympathetic effect Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 244000080208 Canella winterana Species 0.000 description 4
- 235000008499 Canella winterana Nutrition 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229940017545 cinnamon bark Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000001061 forehead Anatomy 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 235000011511 Diospyros Nutrition 0.000 description 3
- 244000236655 Diospyros kaki Species 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 210000005037 parasympathetic nerve Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000037330 wrinkle prevention Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 235000011446 Amygdalus persica Nutrition 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 240000003889 Piper guineense Species 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- -1 sucrose fatty acid ester Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000723438 Cercidiphyllum japonicum Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000624976 Patonia Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000010358 hachimijiogan Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
本発明は、抗ストレス機能や疲労防止機能を有し、更に外的又は内的要因に起因する肌トラブルや肌老化を抑制して肌のキメ改善又はシワの予防・改善に効果がある、漢方処方に関するものである。 The present invention has an anti-stress function and fatigue prevention function, and is effective in improving skin texture or preventing or improving wrinkles by suppressing skin troubles and skin aging caused by external or internal factors. It is about prescription.
ストレスがさまざまな不調や病気を引き起こす要因になっていることが分かってきたことから、最近の医学では、精神的な要素を重視して、心身両面から健康状態をとらえる医療が注目されている。特に、女性の身体は月経周期的でデリケートなホルモンバランスの上で成り立っており、ストレスの影響を受けやすい。
そのため、疲労感を感じたり、肌トラブルを生じたりして、QOLを妨げ快適な生活に対する影響が大きい。
Since it has been found that stress is a cause of various malfunctions and diseases, in recent medicine, medical care that focuses on mental and physical health by focusing on mental elements has attracted attention. In particular, the female body is based on a menstrual cycle and a delicate hormonal balance, and is susceptible to stress.
For this reason, a feeling of fatigue or a skin trouble is caused, and the influence on the comfortable life is disturbed by preventing QOL.
ストレスを受ければ自律神経系の交感神経の興奮により、血圧と心拍数を上昇させ、胃腸・腎臓・皮膚への血流量を減少させ、骨格筋への血液供給量を増やす。
それに対して副交感神経は、体を休ませ体力を回復し、新たなエネルギーを獲得するために、心拍と血圧を下げて、皮膚と胃腸への血液を増やし、瞳孔と細気管支を収縮させて、唾液腺分泌を刺激して、消化器官の蠕動を活発にする。全身のほとんどの器官は交感神経と副交感神経両方の支配を受け、二つの神経系がバランス良く働くことで適正に保たれているが、交感神経と副交感神経のバランスが崩れると疲労感や多汗などの全身症状が現れる。
When stressed, the sympathetic excitement of the autonomic nervous system increases blood pressure and heart rate, decreases blood flow to the gastrointestinal tract, kidneys and skin, and increases blood supply to skeletal muscle.
The parasympathetic nerve, on the other hand, rests the body, restores physical strength, acquires new energy, lowers heart rate and blood pressure, increases blood to the skin and gastrointestinal tract, contracts the pupil and bronchioles, Stimulates salivary gland secretion and activates peristalsis of the digestive tract. Most organs in the whole body are controlled by both sympathetic and parasympathetic nerves, and the two nervous systems work well in balance, but when the sympathetic and parasympathetic nerves are unbalanced, fatigue and sweating Systemic symptoms such as appear.
また、疲労とは、一般に「過度の肉体的または精神的活動により生じた特有の病的不快感と、休養を求める欲求を伴う身体または精神機能の減退状態」と定義され、肉体的疲労、精神的疲労、慢性疲労性症候群が挙げられる。その中、近年、精神的疲労を自覚する人が急増しているため、その原因解明とともに、予防方法及び治療方法の開発が求められている。また、慢性疲労性症候群は、健康に生活していた人が感冒などを引き金にして、それ以降激しい疲労感、微熱、頭痛、筋肉痛、脱力感、抑うつなどの症状を長期間にわたって訴え、健全な生活ができなくなるという疾患で、その原因は全く解明されていない。 Fatigue is generally defined as “a specific pathological discomfort caused by excessive physical or mental activity and a state of reduced physical or mental function with the desire to rest.” Fatigue and chronic fatigue syndrome. Among them, in recent years, the number of people who are conscious of mental fatigue is increasing rapidly, and the development of preventive and therapeutic methods is required along with elucidating the causes. In addition, chronic fatigue syndrome is triggered by a person living in a healthy manner, and the symptoms such as intense fatigue, slight fever, headache, muscle pain, weakness, depression, etc. are reported over a long period of time. It is a disease that makes life impossible, and its cause has not been elucidated at all.
ストレスが及ぼす皮膚への影響に関しては、ストレスがざ瘡(ニキビ)発症悪化に関係することやアトピー性皮膚炎の要因の一つであることが経験的に指摘されており、また円形脱毛症や慢性蕁麻疹などの皮膚疾患とストレスとの関連が知られている。 Regarding the effect of stress on the skin, it has been empirically pointed out that stress is related to the worsening of acne onset and one of the causes of atopic dermatitis. The relationship between stress and skin diseases such as chronic urticaria is known.
また、皮膚は体全体を被っているものであり、外界からさまざまな刺激を受けている。そのため、皮膚の最も重要な機能はバリアー機能であることは言うまでもない。しかし、紫外線や乾燥などの外的要因、加齢などの内的要因によって皮膚は痛めつけられており、そのダメージ蓄積によって確実に疲労し老化していくのである。肌の老化は、皮膚のキメが粗くなり、ハリがなくなってシワが増え、皮膚の黄色化や色素沈着などが進む。また、女性では月経に伴うホルモンバランスの乱れにより肌の状態が変化し、月経トラブルの有訴者ではニキビ、色素沈着のような肌トラブルを引き起こすことが多い。 The skin covers the entire body and receives various stimuli from the outside world. Therefore, it goes without saying that the most important function of the skin is the barrier function. However, the skin is hurt by external factors such as ultraviolet rays and dryness, and internal factors such as aging, and the accumulated damage will surely fatigue and age. Skin aging results in rough skin, no firmness, increased wrinkles, yellowing of the skin and pigmentation. In addition, in women, the state of the skin changes due to disturbance of hormone balance accompanying menstruation, and in many cases, complainants of menstrual troubles cause skin troubles such as acne and pigmentation.
肌の表面には、皮溝といわれる網目状に走っている細い溝があり、その間に、これに囲まれた大小の四角形、菱形、多角形などの扁平に高まっている部分があり、これを皮丘とよぶ。皮溝が細かく浅い溝からできていて、皮丘も全体として滑らかな表面をつくっているとき、キメの細かい肌という。それに対して、皮溝が深く、広くなって目立ち、皮丘も
個々かたまりが目立っているものは、キメの粗い肌という。小児、若い女性の肌に前者が多く、中年以降の人に後者が多い。また、外界の刺激を多く受けている人ほど、キメの粗い肌が多い。
On the surface of the skin, there are thin grooves running in a mesh shape called skin grooves, and there are large and small squares, rhombuses, polygons, etc. surrounded by this, It is called a barn. When the skin groove is made of fine and shallow grooves, and the skin mound also has a smooth surface as a whole, it is called fine skin. On the other hand, the skin with deep and wide skin grooves and conspicuous clumps is called rough skin. The former is more common in the skin of children and young women, and the latter is more common in people after middle age. In addition, the more the skin is exposed, the more rough the skin.
加齢とともに、肌のキメの細かさがなくなり、シワが増えることは自然の摂理であるが、美容上の問題として、皮膚の老化を防ぎ、いつまでも若い肌でありたいという願望もまた自然である。しかし、このような外観上の問題だけでなく、肌のキメが粗い状態を放置すると、皮膚の機能低下を招き、本来のバリアー機能にまで影響を及ぼすことにもなり、生命維持上重要な機能までダメージを与えることになる。 It is a natural providence that the fineness of the skin disappears and wrinkles increase with aging, but as a cosmetic problem, the desire to prevent skin aging and remain young forever is also natural. . However, in addition to such appearance problems, leaving the texture of the skin rough will cause the skin's function to deteriorate and even affect the original barrier function. Will cause damage.
このような肌のキメやシワを改善して肌の衰えという問題を解決するため、化粧品や食品などの形態で多くの技術が開発されてきた。例えば、スキンケア化粧料を使用して、外的要因に起因する肌荒れを抑え肌のキメを整える場合、その化粧料には肌表皮の新陳代謝の促進に有効な成分、角質層の保護に有効な成分、ヒアルロン酸やコラーゲンの合成を促進する成分や抗酸化剤などが提案されている。このような観点からは、新陳代謝を促進するリノレン酸を安定的に配合した抗老化剤(特許文献1)、ソルビトール及び/又はマンニトールとグリセリン及び/又はジグリセリンを配合したキメ改善化粧料(特許文献2)、皮膚浸透指数が2以上であることを特徴とする油性成分を配合したキメ改善化粧料(特許文献3)、オレイン酸エチルを配合したキメを整える効果に優れた化粧料(特許文献4)、ノニル酸バニリルアミドを含有したキメ、シワやたるみを改善する皮膚外用剤(特許文献5)などが開示されている。 Many techniques have been developed in the form of cosmetics and foods in order to solve the problem of skin deterioration by improving the texture and wrinkles of the skin. For example, when skin care cosmetics are used to suppress rough skin caused by external factors and prepare skin texture, the cosmetics contain ingredients that are effective in promoting metabolism of the skin epidermis and ingredients that are effective in protecting the stratum corneum. In addition, components that promote the synthesis of hyaluronic acid and collagen, antioxidants, and the like have been proposed. From such a point of view, an anti-aging agent that stably contains linolenic acid that promotes metabolism (Patent Document 1), and a texture-improving cosmetic that contains sorbitol and / or mannitol and glycerin and / or diglycerin (Patent Document) 2), a texture-improving cosmetic composition containing an oily component characterized by having a skin penetration index of 2 or more (Patent Document 3), and a cosmetic composition excellent in the effect of preparing a texture containing ethyl oleate (Patent Document 4) ), Skin texture containing nonyl acid vanillylamide, a skin external preparation for improving wrinkles and sagging (Patent Document 5), and the like.
食品としては、肌のキメを細かくする米抽出物よりなる美容飲料(特許文献6)、肌の老化によるシワ、たるみ、くすみ、キメの変化を防止するため2種類のムコ多糖とコラーゲンなどとコエンザイムQ10とを有効成分として配合した経口用皮膚老化予防・改善剤(特許文献7)、レチノイド関連オーファン受容体(ROR)活性化剤を含有する老化防止用組成物(特許文献8)などが開示されている。 As foods, beauty drinks made of rice extract that refines skin texture (Patent Document 6), wrinkles, sagging, dullness, and texture due to skin aging, 2 kinds of mucopolysaccharides and collagen, and coenzyme An oral skin aging preventive / improving agent containing Q10 as an active ingredient (Patent Document 7), an anti-aging composition containing a retinoid-related orphan receptor (ROR) activator (Patent Document 8), and the like are disclosed. Has been.
しかしながら、従来の方法では肌のキメ改善効果において十分に満足するものといえず、紫外線や乾燥などの外的要因、加齢などの内的要因に起因する肌トラブルや肌老化を抑制し、さらには粗くなった肌のキメ改善剤、又はシワ予防若しくはシワ改善剤が求められていた。 However, it cannot be said that the conventional method is sufficiently satisfied with the skin texture improvement effect, and it suppresses skin troubles and skin aging caused by external factors such as ultraviolet rays and drying, and internal factors such as aging, There has been a demand for an agent for improving the texture of rough skin, or an agent for preventing or improving wrinkles.
また、シワの改善目的で、コラーゲン産生促進剤(特許文献9)やヒアルロン酸産生促進剤(特許文献10)などが開示されており、それぞれ桂皮エキスや芍薬エキスなどが有効とされているが、これらは対症療法的な手段であり、根本的な解決にならない。 Further, for the purpose of improving wrinkles, collagen production promoters (Patent Document 9) and hyaluronic acid production promoters (Patent Document 10) have been disclosed, and cinnamon extract and glaze extract are each effective. These are symptomatic measures and do not provide a fundamental solution.
シワ防止のその他の提案として、血管内皮細胞の新生阻害による抗老化剤(特許文献11)としてヨクイニンエキスなどが開示されており、微小循環不全に起因する肌荒れの改善を目的としたヨクイニンのような生薬類を含有するストレス緩和用の経口投与組成物(特許文献12)が開示されているが、シワ防止効果との関連は明確でなく、十分な効果が得られるとは言い難い。 As another proposal for preventing wrinkles, Yokuinin extract and the like have been disclosed as an anti-aging agent (Patent Document 11) by inhibiting neovascularization of vascular endothelial cells, such as Yokuinin for the purpose of improving rough skin caused by microcirculatory failure. Although an oral administration composition for stress relief containing herbal medicines (Patent Document 12) has been disclosed, the relationship with the wrinkle prevention effect is not clear, and it cannot be said that sufficient effects are obtained.
一方、ストレスが原因の種々トラブルに関し、茯苓のような菌類のエッセンスを含有する生体環境快適化組成物(特許文献13)、免疫が低下するようなアポトーシスに対して、桂枝茯苓丸他いくつかの漢方薬を有効成分として含有するアポトーシス抑制剤(特許文献14)、冠元顆粒を有効成分として含有する老化抑制剤及び酸化ストレス抑制剤(特許文献15)が開示されているが、いずれもストレスが原因で生じた生体側の機能低下を改善するものであり、ストレスそのものを根本的に取り除くまでには至っていない。 On the other hand, regarding various troubles caused by stress, biocomfort-enhancing composition containing the essence of fungi such as spider (Patent Document 13) An anti-apoptotic agent containing Japanese herbal medicine as an active ingredient (Patent Document 14), an aging inhibitor containing an anti-progenitor granule as an active ingredient, and an oxidative stress inhibitor (Patent Document 15) are both disclosed. It is intended to improve the deterioration of the function on the living body caused by the cause, and has not yet completely removed the stress itself.
疲労倦怠感に対しては、八味地黄丸や人参栄養湯などの漢方薬がよく知られているが、漢方薬以外に、桂皮、芍薬、茯苓のような生薬類にビタミンやアミノ酸などを組み合わせた新規な疲労改善用の内服剤(特許文献16及び17)が提案されている。ここで生薬類を用いているのは、ビタミンとアミノ酸とによる疲労回復効果を促進するために過ぎないことが示唆され、生薬自体の疲労防止効果は示されていない。 For fatigue fatigue, Chinese medicines such as Hachimijiogan and Ginseng Nutrition are well known, but in addition to herbal medicines, new medicines that combine vitamins, amino acids, etc. with herbal medicines such as cinnamon, glaze, and salmon An internal preparation for improving fatigue (Patent Documents 16 and 17) has been proposed. Here, it is suggested that the use of crude drugs is only to promote the fatigue recovery effect by vitamins and amino acids, and the fatigue prevention effect of the crude drug itself is not shown.
以上のように、従来の方法ではストレスや疲労を根治するものではなく、ストレスや疲労が原因として現われた症状を対症的に改善するものであり、ストレスや疲労の根本治療を期待するには十分に満足するものといえなかった。 As described above, conventional methods do not cure stress and fatigue, but symptomatically improve symptoms caused by stress and fatigue, and are sufficient to expect fundamental treatment for stress and fatigue. Could not be said to be satisfied.
本発明は、「抗ストレス・疲労防止作用」を有し、また「肌のキメ改善」「シワの予防又は改善」の効果に優れた組成物又は内服剤を提供することにある。
An object of the present invention is to provide a composition or an internal preparation having an “anti-stress / fatigue-preventing action” and having an excellent effect of “improvement of skin texture” and “prevention or improvement of wrinkles”.
本発明者らは、上記課題を解決するため鋭意研究を行ったところ、桂枝茯苓丸料加ヨクイニンが、抗ストレス・疲労防止作用を有し、肌のキメを改善し、肌の外分泌を促進することにより潤いを与え、シワの予防・改善にも効果が期待できること見出し、本発明を完成させた。 As a result of intensive studies to solve the above-mentioned problems, the inventors of the present invention have the anti-stress / fatigue-preventing effect of Katsushido Karasuma-ryo-yokuinin to improve skin texture and promote skin exocrine secretion. As a result, the present invention was completed by finding that it can be moisturized and can be expected to be effective in preventing and improving wrinkles.
即ち、本発明は、ケイヒ(桂皮)、ブクリョウ(茯苓)、ボタンピ(牡丹皮)、トウニン(桃仁)、シャクヤク(芍薬)、ヨクイニンの混合物からなる肌のキメ改善用又はシワ予防・改善用の組成物或は内服剤である。より具体的には、桂皮2〜5重量部、茯苓2〜5重量部、牡丹皮2〜5重量部、桃仁2〜5重量部、芍薬2〜5重量部、ヨクイニン5〜20重量部である肌のキメ改善用又はシワ予防・改善用の組成物或は内服剤である。さらに具体的には、前記組成物或は内服剤が、桂枝茯苓丸料加ヨクイニンと称される漢方処方である。 That is, the present invention is a composition for skin texture improvement or wrinkle prevention / improvement comprising a mixture of keihi (cinnamon), bukkaku (pepper), button pi (peony skin), tounin (pepper), peonies (glaze), and yakuinin. It is a product or an internal medicine. More specifically, 2 to 5 parts by weight of cinnamon, 2 to 5 parts by weight of peony, 2 to 5 parts by weight of peony, 2 to 5 parts by weight of peony, 2 to 5 parts by weight of glaze, and 5 to 20 parts by weight of yokuinin. A composition for improving skin texture or preventing or improving wrinkles, or an internal preparation. More specifically, the composition or the internal preparation is a Chinese herbal prescription called Keikine Karasuma Yokuinin.
これまで、桂枝茯苓丸料加ヨクイニンが、抗ストレス、疲労防止、肌のキメやシワの改
善などの効果を有することは知られていなかった。また、背景技術にも記載したとおり、桂枝茯苓丸料加ヨクイニンを構成する桂皮、茯苓、芍薬及びヨクイニンなどの生薬には、ストレスや疲労により生じた症状を対症的に改善する効果は開示されているものの、抗ストレス作用や疲労自体を防止する作用は知られていなかった。
So far, it has not been known that Katsushika Testicle Yokainin has effects such as anti-stress, fatigue prevention, and improvement of skin texture and wrinkles. In addition, as described in the background art, herbal medicines such as cinnamon bark, cocoon, glaze, and yokuinin that make up Keishi Karasuma Ryoka Yokuinin have been disclosed to symptomatically improve symptoms caused by stress and fatigue. However, the anti-stress action and the action to prevent fatigue itself have not been known.
本発明の、桂皮、茯苓、牡丹皮、桃仁、芍薬、ヨクイニンの混合物から抽出したエキスを含有する内服剤は、従来より知られていた「月経トラブルに起因するトラブル解消効果」に加え、「抗ストレス・疲労防止作用」「顔面の肌のキメの改善効果」、更には「表皮への水分分泌を活性化し、肌に潤いを与え、シワを予防・改善する効果」を新たに見出した。 The oral preparation containing an extract extracted from a mixture of cinnamon, persimmon, peony skin, peach seed, glaze, and yokuinin of the present invention is known in addition to the conventionally known “problem eliminating effect caused by menstrual trouble” "Stress / fatigue prevention action" "Face skin texture improvement effect", and also "Effects to activate moisture secretion to the skin, moisturize the skin and prevent and improve wrinkles".
以下、本発明についてさらに詳細に説明する。
本発明において使用される生薬は以下のものである。
桂皮は、クスノキ科のケイCinnamomum cassia Blume の樹皮又は周皮の一部を除いたものである。
茯苓は、サルノコシカケ科のマツホドPoria cocos Wolf の菌核で、通例、外層をほとんど除いたものである。
牡丹皮は、ボタン科のボタンPaeonia suffruticosa andrews の根皮である。
桃仁は、バラ科のモモPrunus persica Batsch 又はPrunus persica Batsch var.davidiana Maximowicz の種子である。
芍薬は、ボタン科のシャクヤクPaeonia lactiflora Pallas
の根である。
ヨクイニンは、イネ科のハトムギCoix lacryma-jobi Linne var.mayuen Stapf の種皮を除いた種子である。
Hereinafter, the present invention will be described in more detail.
The crude drugs used in the present invention are as follows.
The cinnamon is obtained by removing a part of the bark or pericyte of Cinnamomum cassia Blue of the camphor family.
The cocoon is a mycorrhiza of the pine moss, Poria cocos Wolf, which is usually removed from the outer layer.
Peony skin is the root bark of the button department button Paeonia suffruticosa andrews.
Taojin is a peach of the Rosaceae, Prunus persica Batsch or Prunus persica Batsch var. It is the seed of davidiana maximowicz.
The glaze is a Peonyia patonia lactiflora Pallas
Is the root of
Yokuinin is a pearl barley of Coix lacryma-jobi Linene var. It is the seed excluding the seed coat of mayuen Stapf.
これら6種類の生薬のうち、桂皮、茯苓、牡丹皮、桃仁及び芍薬の5種類の生薬からなる漢方処方が桂枝茯苓丸である。この桂枝茯苓丸は中国宋時代の医書「金匱要略」に記載されており、月経不順、月経困難症、更年期障害、血の道症、のぼせ症で充血しやすく、足冷え、頭痛、めまい、耳鳴り、肩こりやしみに対して処方される。この桂枝茯苓丸に、民間薬としていぼ取りや皮膚のあれによく使われるヨクイニンを加えた処方、すなわち前述の6種類の生薬からなる漢方処方が桂枝茯苓丸料加ヨクイニンで、お血が原因で起こる皮膚のあれやにきびに用いられる。 Among these six kinds of herbal medicines, Kameda Karasuma is a Kampo prescription consisting of five kinds of herbal medicines such as cinnamon bark, persimmon, peony skin, peach seed and glaze. This katsura testicle is described in a Chinese book of the Chinese era, `` Kin Xin Summary ''. Prescribed for stiff shoulders and spots. This is a prescription that adds Yokuinin, which is often used for wart removal and skin as a folk medicine. Used for skin rashes and acne caused by the cause.
本発明の、桂皮、茯苓、牡丹皮、桃仁、芍薬、ヨクイニンの混合物からなる抗ストレス・疲労防止作用、肌のキメ改善用又はシワ予防・改善用の内服剤は、桂皮2〜5重量部、茯苓2〜5重量部、牡丹皮2〜5重量部、桃仁2〜5重量部、芍薬2〜5重量部、ヨクイニン5〜20重量部からなる混合生薬、または、好ましくは桂皮4重量部、茯苓4重量部、牡丹皮4重量部、桃仁4重量部、芍薬4重量部、ヨクイニン10重量部からなる混合生薬から得られる濃縮エキスまたは乾燥エキス粉末が挙げられる。 An anti-stress / fatigue-preventing action comprising a mixture of cinnamon, cocoon, peony, peony, glaze, and yokuinin of the present invention, 2 to 5 parts by weight of cinnamon for skin texture improvement or wrinkle prevention / improvement, 2 to 5 parts by weight of cocoon, 2 to 5 parts by weight of peony skin, 2 to 5 parts by weight of peach seed, 2 to 5 parts by weight of glaze, 5 to 20 parts by weight of yokuinin, or preferably 4 parts by weight of cinnamon, A concentrated extract or dry extract powder obtained from a mixed herbal medicine consisting of 4 parts by weight, 4 parts by weight of peony skin, 4 parts by weight of peony, 4 parts by weight of glaze, and 10 parts by weight of yokuinin.
これら6種類の生薬の合計重量に対して5〜25倍量、好ましくは8〜20倍量の水を加えて、通常80〜100℃で30分間〜2時間加熱してエキスを煎出する。次に煎出液を熱時濾過して固形成分を除去し、この抽出液を濃縮し生薬抽出液が得られる。さらに、通常の乾燥方法、例えばスプレードライ、減圧濃縮乾燥、凍結乾燥等により乾燥することもできる。このようにして得られたエキス粉末はそのままの形で使用することもできるが
、通常、食品及び/又は医薬品に使用される通常の賦形剤(例えば、結晶セルロース、ショ糖脂肪酸エステル、白糖等)を加え、例えば、乾式造粒法或は湿式造粒法により造粒して製造し、このようにした造粒物をそのまま使用することもできるが、それらをさらに打錠機を用いた圧縮成形物として使用することもできる。
The extract is decocted by adding 5 to 25 times, preferably 8 to 20 times the amount of water with respect to the total weight of these six kinds of herbal medicines, and usually heating at 80 to 100 ° C. for 30 minutes to 2 hours. Next, the decoction is filtered while hot to remove the solid components, and this extract is concentrated to obtain a herbal extract. Furthermore, it can also be dried by ordinary drying methods such as spray drying, vacuum concentration drying, freeze drying and the like. Although the extract powder thus obtained can be used as it is, it is usually used as usual excipients for food and / or pharmaceuticals (for example, crystalline cellulose, sucrose fatty acid ester, sucrose, etc. ), For example, granulated by dry granulation method or wet granulation method, and such granulated products can be used as they are, but they are further compressed using a tableting machine. It can also be used as a molded product.
また、漢方エキスが特有のえぐみを有することから、マスキングした製剤が服用上好ましく、被覆剤で被覆したフィルムコート剤とすることもできる。また、成分の安定性の点や簡単に摂取できる形態として、粉砕したものをそのまままた上記造粒物をハードカプセルやソフトカプセルに充填し摂取してもよい。 In addition, since the Kampo extract has a peculiar taste, a masked preparation is preferable for taking, and a film coating agent coated with a coating agent can also be obtained. In addition, as a component stability point and a form that can be easily ingested, the pulverized product may be used as it is or filled with the above granulated product in a hard capsule or soft capsule.
或いは、各生薬をそれぞれ個別に抽出したエキスを混合して、前述した同様の方法により使用することもできる。 Alternatively, extracts obtained by individually extracting each herbal medicine can be mixed and used by the same method as described above.
また、抽出したエキスに、通常、液状の食品などに使用される甘味料、酸味料、乳化剤、フレーバー、分散助剤などの賦形剤を加えて溶解し、液体の形状として製造することもできる。 In addition, the extracted extract can be dissolved in a liquid form by adding excipients such as sweeteners, acidulants, emulsifiers, flavors, and dispersion aids that are usually used in liquid foods. .
以上のような、内服固形の顆粒、錠剤、散剤、液剤の形態だけではなく、半固形状の形態のもの及び、水や湯などに溶解し液状にして用いることができる粉末状の形態などに加工することもできる。
As described above, not only in the form of internal solid granules, tablets, powders, and liquids, but also in semi-solid forms and powdered forms that can be dissolved and used in water or hot water. It can also be processed.
以下に試験例を挙げて本発明を詳細に説明する。
(試験例1)
女性は月経に伴うホルモンの著しい変化によって、心身に周期性の変化があることが知られている。そこで、キメに対する内服剤効果の確認するため、月経周期変動の影響を考慮し、黄体期に試験方法記載の肌計測を行なった後、月経初日から実施例1の製剤を1回4錠、1日2回の服用を開始し、次の月経期まで各周期に同様の肌計測を行った。
(1)試験方法
22歳から40歳の健常成人女性12名を対象に、肌状態を全顔画像撮影・画像解析システム(ロボスキンアナライザー)(株式会社インフォワード社製)を用いた肌評価により、頬部のキメ、表皮水分の測定、分極電流計による頬部及び額部の真皮水分の測定を行なった。尚、キメの評価は、モノクロ画像における暗部を皮溝、明部を皮丘とし、明部暗部をそれぞれ強調処理して二値化した結果が、一辺0.4mmの正三角形のキメモデルに近ければ近いほど、100点満点中の高い点となるように計測し評価される。
Hereinafter, the present invention will be described in detail with reference to test examples.
(Test Example 1)
It is known that women have periodic changes in mind and body due to significant changes in hormones associated with menstruation. Therefore, in order to confirm the effect of internal use on texture, after taking the skin measurement described in the test method in the luteal phase in consideration of the influence of menstrual cycle variation, 4 tablets of the formulation of Example 1 once from the first day of menstruation, 1 Taking twice a day, the same skin measurement was performed in each cycle until the next menstrual period.
(1) Test method For 12 healthy adult women aged 22 to 40 years old, the skin condition was evaluated by skin evaluation using a full-face image capturing and image analysis system (Robo Skin Analyzer) (manufactured by Inforward Co., Ltd.). The texture of the cheeks and the skin moisture were measured, and the dermis moisture in the cheeks and forehead was measured with a polarization ammeter. Note that the evaluation of the texture is such that the dark part in the monochrome image is a skin groove, the bright part is a skin hill, and the result of binarization by emphasizing the bright part dark part is close to a regular triangle texture model with a side of 0.4 mm. It is measured and evaluated so that the closer it is, the higher the score is out of 100 points.
(2)試験結果
試験結果を表1及び2に示した。実施例1の内服剤の服用により、キメスコアは有意に改善した。また、黄体ホルモンの影響により身体に水分が貯留しやすい黄体期に、内服剤の服用により表皮水分が有意に増加した。加えて、貯留した水分の排泄が損なわれることでトラブルが生じやすい月経期に、真皮水分が有意に低下した。この結果より、真皮層に滞った水分の分泌が活性化され、表皮水分が増加して、肌に潤いが生じたことが示唆された。
(2) Test results The test results are shown in Tables 1 and 2. By taking the internal preparation of Example 1, the texture score was significantly improved. In addition, during the luteal phase, where the body easily retains water due to the effects of luteinizing hormone, epidermal moisture increased significantly by taking the internal preparation. In addition, dermal moisture was significantly reduced during the menstrual period, when the excretion of stored water was impaired and trouble was likely to occur. From this result, it was suggested that the secretion of water stagnated in the dermis layer was activated, the epidermal water increased, and the skin was moistened.
(試験例2)
表皮水分とシワの関連性を確認するため、頬部及び額部の月経周期による変化について評価した。
(Test Example 2)
In order to confirm the relationship between epidermal water and wrinkles, changes in the cheek and forehead due to the menstrual cycle were evaluated.
(1)試験方法
24歳から40歳の健常成人女性13名を対象に、月経周期(卵胞期、排卵期、黄体期、月経期)ごとに、肌状態を全顔画像撮影・画像解析システム(ロボスキンアナライザー)(株式会社インフォワード社製)を用いて、シワ及び表皮水分の測定を行なった。
(1) Test method For all 13 healthy adult women aged 24 to 40 years old, the skin condition of the whole face imaging and image analysis system for each menstrual cycle (follicular phase, ovulation phase, luteal phase, menstrual phase) ( Using a Robo Skin Analyzer (manufactured by Inforward Co., Ltd.), wrinkles and skin moisture were measured.
(2)試験結果
頬部及び額部の表皮水分は、月経周期変化に個体差があったが、平均すると周期による有意な変動は認められなかった。周期ごとに分けで表皮水分と目尻のシワ長の関係を評価した結果、図1〜3に示したように、表皮水分とシワには有意な負の相関が認められ、表皮水分値が高いほどシワが少ないことが確認された。従って、試験例1で示した表皮水分の増加は、シワの予防・改善効果を示唆するものである。
(2) Test results The epidermal water content in the cheeks and forehead had individual differences in menstrual cycle changes, but on average, no significant variation was observed due to the cycle. As a result of evaluating the relationship between the epidermal water content and the wrinkle length of the corners of the eyes divided by period, as shown in FIGS. 1 to 3, a significant negative correlation was observed between the epidermal water content and the wrinkle. It was confirmed that there were few wrinkles. Therefore, the increase in epidermal water shown in Test Example 1 suggests the effect of preventing and improving wrinkles.
(試験例3)
疲労及びストレスに対する内服剤効果確認するため、黄体期に試験方法記載の疲労評価と交感神経の活動レベルの測定を行なった後、月経初日から実施例1の製剤を1回4錠、1日2回の服用を開始し、次の月経期まで各周期に同様の測定を行った。
(Test Example 3)
In order to confirm the effect of internal use on fatigue and stress, after the fatigue evaluation described in the test method and the measurement of the level of sympathetic nerve activity were performed in the luteal phase, 4 tablets of the preparation of Example 1 once a day, 2 times a day The same measurement was performed at each cycle until the next menstrual period.
・ 試験方法
22歳から40歳の健常成人女性12名を対象に、POMS(Profile of Mood Status)を用いた疲労の評価と、分極電流計による額部の皮膚コンダクタンス測定を行なった。
Test Method For 12 healthy adult women aged 22 to 40 years old, fatigue evaluation using POMS (Profile of Mood Status) and skin conductance measurement of the forehead using a polarization ammeter were performed.
(2)試験結果
試験結果を表4及び5に示した。服用前の疲労スコアにより高値群(n=6)と低値群(n=6)で分割し、内服剤の服用による変化を解析したところ、表4に示すように、疲労スコアの高値群では内服剤の服用により、疲労スコアが有意に低下した。また、皮膚コンダクタンスを測定することにより交感神経の活動レベルを示すAP値は、表5に示すように、内服剤の服用により、AP値が有意に低下した。以上のように、実施例1の製剤の服用することで交感神経系の興奮を抑制し、疲労感も軽減することが確認され、この結果は、疲労防止及び抗ストレス効果を示唆するものである。
(2) Test results The test results are shown in Tables 4 and 5. By dividing the high score group (n = 6) and the low score group (n = 6) according to the fatigue score before taking, and analyzing the change due to the internal use, as shown in Table 4, in the high fatigue score group The fatigue score decreased significantly with the internal use. In addition, as shown in Table 5, the AP value indicating the level of sympathetic nerve activity by measuring skin conductance significantly decreased as a result of internal use. As described above, it was confirmed that the sympathetic nervous system excitement was suppressed by taking the preparation of Example 1, and the fatigue feeling was also reduced. This result suggests anti-fatigue and anti-stress effects. .
以下に、実施例および比較例を挙げて本発明をさらに具体的に説明する。 Hereinafter, the present invention will be described more specifically with reference to examples and comparative examples.
(実施例1)
桂枝茯苓丸料加ヨクイニンフィルムコート錠
(素錠部)
桂枝茯苓丸料加ヨクイニンエキス粉末* 1800g
結晶セルロース 380g
クロスカルメロースナトリウム 300g
含水二酸化ケイ素 130g
ステアリン酸マグネシウム 30g
小 計 2640g
(剤皮部)
ヒプロメロース 82g
酸化チタン 14g
カルナウバロウ 微量
小 計 96g
合 計 2736g
*桂枝茯苓丸料加ヨクイニンエキス粉末1800mgは、桂皮2g、茯苓2g、牡丹皮2g、桃仁2g、芍薬2g、ヨクイニン5gの混合物から熱水で抽出し乾燥して得られる。
Example 1
Keishi Karasuma Ryoko Yokuinin Film Coat Tablets
(Uncoated part)
Keishi Karasuma Yakuinin Extract Powder * 1800g
380 g of crystalline cellulose
Croscarmellose sodium 300g
Hydrous silicon dioxide 130g
Magnesium stearate 30g
Subtotal 2640g
(Skin part)
Hypromellose 82g
Titanium oxide 14g
Carnauba wax Subtotal 96g
Total 2736g
* 1800 mg of Keishibuchi Karasuma Yokuinin Extract Powder is obtained by extracting with hot water from a mixture of 2 g of cinnamon bark, 2 g of strawberry, 2 g of peony skin, 2 g of peach seed, 2 g of glaze and 5 g of yokuinin and drying.
(製造方法)
「日局」製剤総則、錠剤の項に準じて錠剤を製する。すなわち上表に記載の、桂枝茯苓丸料加ヨクイニンエキス粉末からステアリン酸マグネシウムまでの成分をとり、一錠重量330mgの錠剤を製し、その錠剤に上表の剤皮部ヒプロメロースからカルナウバロウを用いて、コーティングを施し、実施例1のフイルムコーティング錠(一錠重量342mg
桂枝茯苓丸料加ヨクイニンエキス粉末225mg含有)を得た。
(Production method)
Prepare tablets according to “JP” General Rules for Preparations, Tablets. That is, take the ingredients from katsushi testicles added Yokuinin extract powder to magnesium stearate as shown in the table above, and make a tablet with a tablet weight of 330 mg, and use carnauba wax from the skin part hypromellose in the table above The film-coated tablets of Example 1 (one tablet weight 342 mg)
And 225 mg of Yakuinin extract powder).
(実施例2)
桂枝茯苓丸料加ヨクイニン錠
桂枝茯苓丸料加ヨクイニンエキス粉末 1800g
結晶セルロース 380g
クロスカルメロースナトリウム 300g
含水二酸化ケイ素 130g
ステアリン酸マグネシウム 30g
合 計 2640g
(Example 2)
Keishi Karasuma Ryoko Yokuinin Tablet
Katsushika Karasuma Yokuinin Extract Powder 1800g
380 g of crystalline cellulose
Croscarmellose sodium 300g
Hydrous silicon dioxide 130g
Magnesium stearate 30g
Total 2640g
(製造方法)
「日局」製剤総則、錠剤の項に準じて錠剤を製する。すなわち上表に記載の、桂枝茯苓丸料加ヨクイニンエキス粉末からステアリン酸マグネシウムまでの成分をとり錠剤(一錠重量330mg 桂枝茯苓丸料加ヨクイニンエキス粉末225mg含有)を製し、本発明の実施例2の錠剤を得た。
(Production method)
Prepare tablets according to “JP” General Rules for Preparations, Tablets. That is, taking the ingredients from the Katsushido testicles added Yokuinin extract powder to magnesium stearate as shown in the above table to produce a tablet (one tablet weight 330 mg containing Keishibuchi testicles added Yokuinin extract powder 225 mg), The tablet of Example 2 was obtained.
(実施例3)
桂枝茯苓丸料加ヨクイニン錠
(素錠部)
桂枝茯苓丸料エキス粉末* 1150g
ヨクイニンエキス粉末** 390g
結晶セルロース 400g
クロスカルメロースナトリウム 300g
含水二酸化ケイ素 130g
ステアリン酸マグネシウム 30g
合 計 2400g
*桂枝茯苓丸料加ヨクイニンエキス粉末1800mgは、桂皮2g、茯苓2g、牡丹皮2g、桃仁2g、芍薬2gの混合物から熱水で抽出し乾燥して得られる。
**ヨクイニンエキス粉末は、ヨクイニン5gから熱水で抽出し乾燥して得られる。
Example 3
Keishi Karasuma Ryoko Yokuinin Tablet
(Uncoated part)
Keishi Testicle Extract Powder * 1150g
Yokuinin Extract Powder ** 390g
400g of crystalline cellulose
Croscarmellose sodium 300g
Hydrous silicon dioxide 130g
Magnesium stearate 30g
Total 2400g
* Keiseki Karasuma Yakuinin Extract Powder 1800 mg is obtained by extracting with hot water from a mixture of 2 g of cinnamon bark, 2 g of persimmon, 2 g of peony skin, 2 g of peach seed and 2 g of glaze and drying.
** Yokuinin extract powder is obtained by extracting from 5 g of Yokuinin with hot water and drying.
(製造方法)
「日局」製剤総則、錠剤の項に準じて錠剤を製する。すなわち上表に記載の、桂枝茯苓丸料エキス粉末からステアリン酸マグネシウムまでの成分をとり、(一錠重量300mg )を製し、本発明の実施例3の錠剤を得た。
(Production method)
Prepare tablets according to “JP” General Rules for Preparations, Tablets. That is, the ingredients from Katsushido testicle extract powder to magnesium stearate described in the above table were taken to produce (tablet weight 300 mg) to obtain a tablet of Example 3 of the present invention.
(実施例4)
桂枝茯苓丸料加ヨクイニン顆粒剤
桂枝茯苓丸料加ヨクイニンエキス粉末 1800g
乳糖 2550g
ヒドロキシプロピルセルロース 150g
合 計 4500g
Example 4
Keishi Karasuma Ryoko Yokuinin Granules
Katsushika Karasuma Yokuinin Extract Powder 1800g
Lactose 2550g
Hydroxypropylcellulose 150g
Total 4500g
(製造方法)
「日局」製剤総則、錠剤の項に準じて顆粒剤を製する。すなわち上表に記載の、桂枝茯苓丸料加ヨクイニンエキス粉末からヒドロキシプロピルセルロースまでの成分をとり、実施例4の顆粒剤を得た。
(Production method)
Granules are prepared according to the “JP” general rules for preparations and tablets. That is, the ingredients described in the above table, from Katsushika testicle additive Yokuinin extract powder to hydroxypropyl cellulose, were used to obtain granules of Example 4.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008223166A JP5661994B2 (en) | 2008-01-04 | 2008-09-01 | Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008000021 | 2008-01-04 | ||
JP2008000021 | 2008-01-04 | ||
JP2008223166A JP5661994B2 (en) | 2008-01-04 | 2008-09-01 | Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009179625A JP2009179625A (en) | 2009-08-13 |
JP5661994B2 true JP5661994B2 (en) | 2015-01-28 |
Family
ID=41033864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008223166A Active JP5661994B2 (en) | 2008-01-04 | 2008-09-01 | Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5661994B2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4666537B1 (en) * | 2010-01-21 | 2011-04-06 | 株式会社資生堂 | Wrinkle improving beauty set and beauty method using the same |
CN103766887A (en) * | 2012-10-26 | 2014-05-07 | 苏州市洋海电子有限公司 | Preparation comprising astragalus mongholicus extract |
CN103766888A (en) * | 2012-10-26 | 2014-05-07 | 苏州市洋海电子有限公司 | Preparation containing American ginseng extract |
CN103766882A (en) * | 2012-10-26 | 2014-05-07 | 苏州市洋海电子有限公司 | Compound astragalus mongholicus preparation |
CN103798758A (en) * | 2012-11-07 | 2014-05-21 | 苏州市洋海电子有限公司 | Preparation containing ginkgo leaf extract |
CN103798774A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Compound poria cocos preparation |
CN103798771A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Traditional Chinese medicine extract-containing compound preparation |
CN103798772A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Health-care product composition |
CN103798773A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Health-care product |
CN104523902B (en) * | 2015-01-26 | 2016-09-14 | 南阳理工学院 | A kind of Chinese medicine composition reversing oophoroma multidrug resistance based on Ramulus Cinnamomi Poria pill |
CN104645253A (en) * | 2015-03-23 | 2015-05-27 | 贾学亮 | Patch for preventing and treating dyspepsia |
CN104825982B (en) * | 2015-06-05 | 2018-09-28 | 张宝山 | A kind of Chinese medicine preparation and preparation method for treating digestive diseases |
CN107281295A (en) * | 2017-07-17 | 2017-10-24 | 昆药集团血塞通药业股份有限公司 | It is a kind of that there is pharmaceutical composition of promotion digestion and preparation method thereof |
JP7523889B2 (en) * | 2019-03-26 | 2024-07-29 | 小林製薬株式会社 | Pharmaceutical composition for improving activity level |
KR102192573B1 (en) * | 2020-08-12 | 2020-12-18 | 문종진 | Composition for preventing and improving menstrual pain and skin troubles |
CN112869159A (en) * | 2021-02-04 | 2021-06-01 | 建昌帮药业有限公司 | Anti-wrinkle health product containing folic acid |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3536111B2 (en) * | 1992-06-29 | 2004-06-07 | 株式会社ナリス化粧品 | Mucopolysaccharide fragmentation inhibitor and cosmetic |
JP3807782B2 (en) * | 1995-06-22 | 2006-08-09 | ライオン株式会社 | Hyaluronidase inhibitor |
JP5106739B2 (en) * | 2000-06-29 | 2012-12-26 | クイック−メッド テクノロジーズ、インク. | Cosmetic compositions and methods |
JP2003252778A (en) * | 2002-02-27 | 2003-09-10 | Showa Sangyo Co Ltd | Hyaluronidase inhibitor and cosmetic, beverage, food or medicine containing the same |
JP2004083449A (en) * | 2002-08-26 | 2004-03-18 | Kinji Ishida | Orally administrative composition for stress relaxation |
-
2008
- 2008-09-01 JP JP2008223166A patent/JP5661994B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009179625A (en) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5661994B2 (en) | Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect | |
CN105213971B (en) | The Chinese medicine composition for treating psoriasis | |
CN104524186B (en) | A kind of anti-fatigue medicament and preparation method thereof | |
TW201345538A (en) | Use of antrodia camphorata for treating skin conditions | |
CN107510736A (en) | The Chinese medicine composition of eye strain is alleviated in a kind of external application | |
KR20130003655A (en) | Composition for prevention of hair loss and promotion of hair growth which contains rosa multiflora extract as an active ingredient | |
JP2003146895A (en) | Tablet including ephippium | |
CN104208425B (en) | A kind of Chinese medicine preparation for being used to nurse one's health critical hypertension | |
CN108703917B (en) | Anti-aging composition and cosmetic prepared from same | |
CN103341074A (en) | Application of Yixuanning granules in preparation of medicaments for treating insomnia | |
CN106720822A (en) | A kind of chocolate with invigorating the lung and benefiting vital QI effect | |
JP2019195309A (en) | Genus acacia bark-derived substance-containing skin moisturizing composition | |
CN105168739B (en) | A kind of treat hypertension, hyperlipidemia, hyperglycemia and the compositions of resisting fatigue improving eyesight | |
CN109758497B (en) | Traditional Chinese medicine composition and medicine for chronic heart failure and preparation method and application thereof | |
TW200528033A (en) | Oral skin-improving pharmaceutical preparation using cranberry abstract as active principle | |
CN105535587A (en) | Traditional Chinese medicinal preparation for treating heart and kidney disharmony type palpitation and insomnia and preparation method of traditional Chinese medicinal preparation | |
CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
CN110269897A (en) | Composition and application thereof that is a kind of antifatigue and improving sleep | |
KR102677730B1 (en) | Peptide for lipolysis and their uses | |
JP6026706B2 (en) | Skin symptom improving agent, hair restorer or slimming agent | |
JP6378926B2 (en) | Composition for lowering blood glucose level | |
CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
CN110064024A (en) | The Chinese medicine composition and Babu plaster and its preparation process of a kind of nti-freckle | |
JP7523889B2 (en) | Pharmaceutical composition for improving activity level | |
WO2024079251A1 (en) | Non-therapeutic use of a composition comprising oleuropein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120312 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130423 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130614 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130719 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5661994 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |